POLR3D Antibody

What is POLR3D and why is it significant for research?

POLR3D is a specific peripheric component of RNA polymerase III (Pol III) that catalyzes the transcription of DNA into RNA using ribonucleoside triphosphates as substrates. Its significance extends beyond basic transcription, as it plays crucial roles in synthesizing small non-coding RNAs including 5S rRNA, snRNAs, tRNAs, and miRNAs from at least 500 distinct genomic loci. POLR3D assembles with POLR3E/RPC5 to form a subcomplex that binds the Pol III core, enabling recruitment at transcription initiation sites and driving transcription from both type 2 and type 3 DNA promoters . Beyond transcription, POLR3D functions as a nuclear and cytosolic DNA sensor in innate immunity, able to detect non-self dsDNA that serves as template for transcription into dsRNA, thereby inducing type I interferon and NF-kappa-B through the RIG-I pathway .

Which applications are POLR3D antibodies validated for?

POLR3D antibodies have been validated for multiple experimental applications. The rabbit polyclonal POLR3D antibody from Abcam (ab86786) is specifically validated for Western blotting (WB), immunoprecipitation (IP), and immunohistochemistry on paraffin-embedded sections (IHC-P) with human samples . Other antibodies like the PACO22314 have been validated for Western blotting and ELISA techniques with human samples . When selecting an antibody for your research, it's essential to verify that it has been validated for your specific application and species of interest, as different antibodies may have different optimal conditions and performance characteristics across applications.

What is the recommended protocol for Western blotting with POLR3D antibodies?

For Western blotting with POLR3D antibodies, researchers should follow these methodological guidelines: First, prepare protein extracts from your samples of interest (e.g., cell lysates). For the Abcam antibody (ab86786), use a dilution range of 0.04-1 μg/mL for detection . For the PACO22314 antibody, a dilution range of 1:500-1:3000 is recommended . Separate proteins using SDS-PAGE and transfer to an appropriate membrane. Block the membrane with a suitable blocking buffer, then incubate with the primary POLR3D antibody at the recommended dilution overnight at 4°C. After washing, incubate with an appropriate HRP-conjugated secondary antibody, such as goat anti-rabbit IgG . Develop using chemiluminescence detection methods. When analyzing results, the expected molecular weight of POLR3D is approximately 44 kDa .

How should researchers optimize immunohistochemistry protocols with POLR3D antibodies?

When optimizing immunohistochemistry protocols with POLR3D antibodies, researchers should begin with formalin/PFA-fixed paraffin-embedded tissue sections. For the ab86786 antibody, a starting dilution of 1/1000 (0.2μg/ml) has been validated for human prostate carcinoma tissue . The protocol should include appropriate antigen retrieval (typically heat-induced epitope retrieval in citrate buffer pH 6.0 or EDTA buffer pH 9.0), blocking of endogenous peroxidase activity, and protein blocking to minimize background. Following primary antibody incubation, use a suitable detection system like DAB (3,3'-diaminobenzidine) for visualization . Counterstain with hematoxylin to provide contrast. Optimization might require testing different antibody concentrations, incubation times, and antigen retrieval methods. Always include positive and negative controls to ensure specificity of staining and to help distinguish between specific signal and background.

How can researchers verify POLR3D antibody specificity in innate immune response studies?

Verifying POLR3D antibody specificity in innate immune response studies requires a multi-faceted approach. First, perform side-by-side comparisons with different POLR3D antibodies targeting distinct epitopes to confirm consistent localization patterns. Second, implement genetic validation through POLR3D knockdown (siRNA/shRNA) or knockout (CRISPR-Cas9) approaches, which should eliminate or significantly reduce antibody signal in Western blots and immunostaining . Third, conduct immunoprecipitation followed by mass spectrometry to confirm that the antibody is pulling down POLR3D and known interacting partners. For innate immune studies specifically, validate antibody performance in both resting cells and after stimulation with DNA viruses or bacterial DNA, as POLR3D localization may change during immune activation . Finally, conduct functional validation by demonstrating that antibody-mediated neutralization of POLR3D disrupts its role in sensing non-self DNA and subsequent type I interferon and NF-kappa-B induction through the RIG-I pathway.

What are the key considerations when using POLR3D antibodies to study viral sensing mechanisms?

When using POLR3D antibodies to study viral sensing mechanisms, researchers must consider several critical factors. First, experimental timing is crucial – POLR3D's role in DNA sensing and subsequent activation of innate immune pathways is dynamic, so time-course experiments are essential to capture the full activation and resolution phases of the response . Second, subcellular localization analysis using fractionation methods or confocal microscopy with co-localization studies is important, as POLR3D functions in both nuclear and cytosolic compartments depending on the context of viral infection . Third, researchers should implement appropriate viral models, including DNA viruses like Epstein-Barr virus (EBV), which produces EBERs that are recognized by the POLR3D-mediated sensing pathway . Fourth, researchers should conduct parallel analyses of downstream signaling components of the RIG-I pathway and measure interferons and NF-kappa-B activation to correlate POLR3D activity with functional outcomes. Finally, specificity controls must be implemented, including comparison of host responses to DNA versus RNA viruses, as POLR3D's sensing function is primarily associated with DNA pathogens.

How can researchers differentiate between POLR3D's transcriptional and innate immune functions experimentally?

Differentiating between POLR3D's transcriptional and innate immune functions requires sophisticated experimental approaches. First, use subcellular fractionation followed by immunoblotting with POLR3D antibodies to quantify the distribution between nuclear (predominantly transcriptional) and cytosolic (predominantly immune sensing) pools . Second, implement chromatin immunoprecipitation (ChIP) using POLR3D antibodies to assess binding to known Pol III transcriptional targets (tRNAs, 5S rRNA genes) versus immunoprecipitation of cytosolic complexes to identify immune sensing complexes. Third, develop domain-specific antibodies or use tagged mutant constructs that selectively disrupt either function. Fourth, conduct temporal studies after pathogen exposure, as transcriptional roles may predominate under homeostatic conditions while immune sensing functions activate upon pathogen detection. Fifth, use cell-type specific analyses, comparing specialized immune cells with high innate immune activity versus cells with prominent Pol III transcriptional demands. Finally, correlate POLR3D binding (by immunoprecipitation) with different RNA outputs – structured non-coding RNAs (transcriptional function) versus immunostimulatory RNAs that activate RIG-I (immune function) – using RNA sequencing and functional assays.

What strategies can address non-specific binding when using POLR3D antibodies in co-immunoprecipitation studies?

To address non-specific binding in co-immunoprecipitation studies with POLR3D antibodies, researchers should implement several optimization strategies. First, conduct careful antibody titration experiments to determine the minimum effective concentration that yields specific signal while minimizing background; for example, ab86786 has been successfully used at 10 μg/mg lysate for immunoprecipitation . Second, optimize lysis and binding buffers by adjusting salt concentration, detergent type/concentration, and pH to maintain specific interactions while disrupting non-specific bindings. Third, implement extensive pre-clearing steps using control IgG and protein A/G beads to remove proteins that bind non-specifically to antibodies or beads. Fourth, include appropriate controls including "no antibody" controls, isotype-matched irrelevant antibodies, and when possible, samples with POLR3D knockdown or knockout. Fifth, consider using crosslinking techniques like DSP (dithiobis[succinimidylpropionate]) to stabilize genuine protein-protein interactions before cell lysis. Sixth, for detecting interactions within the RNA polymerase III complex specifically, consider validating co-immunoprecipitated partners by blotting for known POLR3D interactors like POLR3E/RPC5 .

How do different commercial POLR3D antibodies compare in terms of epitope recognition and performance?

Different commercial POLR3D antibodies vary significantly in their epitope recognition and performance characteristics, making proper selection crucial for experimental success. The Abcam antibody (ab86786) targets a synthetic peptide within human POLR3D amino acids 150-250 , while the Assay Genie antibody (PACO22314) is generated against a synthesized peptide derived from an internal region of human RPC4 (POLR3D) . This epitope difference may influence antibody accessibility to the target in different experimental conditions, particularly when POLR3D is engaged in protein complexes that might mask certain epitopes. Performance-wise, the Abcam antibody is validated for Western blotting, immunoprecipitation, and immunohistochemistry, with demonstrated applications in human prostate carcinoma tissue . The Assay Genie antibody shows validation for ELISA and Western blotting, with testing specifically in MCF-7 cells . When selecting an antibody, researchers should consider whether the epitope is accessible in their experimental system and whether the antibody has been validated in applications and cell/tissue types relevant to their research question.

What are the key differences in POLR3D expression and function across different cell types and how does this impact antibody selection?

POLR3D expression and function exhibit significant cell type-specific variations that directly impact antibody selection strategies. While POLR3D is broadly expressed as a component of the essential RNA polymerase III machinery, its relative abundance and specific functions may vary considerably. In immune cells, the DNA-sensing function may be more prominent, whereas in rapidly dividing cells with high protein synthesis requirements, the transcriptional role in producing tRNAs and 5S rRNAs may predominate . Cell-type variations in post-translational modifications, complex formation, and subcellular localization can affect epitope accessibility and antibody binding efficiency. For example, when studying POLR3D in cancer cells like MCF-7 or HeLa, antibodies validated specifically in these cell lines should be prioritized . When examining tissues rather than cell lines, researchers should verify that their selected antibody has been validated for tissue applications, as the ab86786 antibody has been for prostate carcinoma . Additionally, species cross-reactivity must be considered, as both discussed antibodies are specifically validated for human samples , which may limit their utility in model organism research without additional validation.

How can researchers quantitatively assess POLR3D levels in response to viral infection or immune stimulation?

Quantitative assessment of POLR3D levels during viral infection or immune stimulation requires a multi-modal approach for comprehensive analysis. Western blotting with POLR3D antibodies provides a direct measure of protein levels, with densitometric analysis normalized to loading controls like β-actin . For this application, antibody dilutions must be optimized within the linear detection range (e.g., 1:500-1:3000 for PACO22314 or 0.04-1 μg/mL for ab86786 ). For higher throughput analysis, ELISA-based methods can be employed, with PACO22314 recommended at dilutions of 1:2000-1:10000 . To distinguish between subcellular pools, which is particularly important as POLR3D shuttles between nuclear and cytosolic compartments during immune activation, subcellular fractionation followed by immunoblotting or immunofluorescence microscopy with quantitative image analysis should be performed. For deeper mechanistic insights, researchers should couple protein-level measurements with assessment of POLR3D activity by measuring: (1) transcriptional output of Pol III targets using RT-qPCR; (2) chromatin association using ChIP-qPCR; and (3) downstream immune activation markers like type I interferons and NF-κB activation to correlate POLR3D levels with functional outcomes.

What are the optimal sample preparation methods for detecting POLR3D in different subcellular compartments?

Optimal sample preparation for detecting POLR3D in different subcellular compartments requires compartment-specific extraction protocols. For whole-cell lysates, which provide an overview of total POLR3D levels, standard RIPA buffer extraction has been successfully used with both ab86786 and PACO22314 antibodies . For nuclear extracts enriched for the transcriptionally active pool of POLR3D, researchers should use gentle nuclear extraction buffers (e.g., 10mM HEPES pH 7.9, 10mM KCl, 1.5mM MgCl₂, 0.34M sucrose, 10% glycerol, 1mM DTT with protease inhibitors) followed by nuclear lysis. For cytosolic fractions containing the immune-sensing pool of POLR3D, collect the cytosolic fraction after plasma membrane permeabilization but before nuclear lysis. For chromatin-bound POLR3D, implement additional extraction with nuclease treatment (e.g., benzonase or DNase I) after nuclear isolation. When preparing samples for immunohistochemistry, formalin/PFA-fixation followed by paraffin embedding has been validated for POLR3D detection , but optimal antigen retrieval conditions may need to be determined empirically. For all fractionation approaches, verify compartment-specific enrichment using markers like lamin B (nuclear envelope), GAPDH (cytosol), and histone H3 (chromatin) alongside POLR3D detection.

What controls are essential when interpreting POLR3D antibody staining patterns in immunofluorescence?

When interpreting POLR3D antibody staining patterns in immunofluorescence, several essential controls must be implemented for reliable data interpretation. First, include a negative control omitting the primary antibody while maintaining all other conditions to assess secondary antibody non-specific binding. Second, implement biological negative controls using POLR3D knockdown or knockout cells to confirm specificity of the observed signal. Third, include positive controls in tissues or cells known to express POLR3D at detectable levels, such as HeLa cells or MCF-7 cells . Fourth, perform subcellular marker co-staining to confirm the expected dual localization of POLR3D in both nuclear and cytosolic compartments , using markers such as DAPI (nucleus), lamin B (nuclear envelope), and tubulin (cytoskeleton). Fifth, conduct peptide competition assays, where pre-incubation of the antibody with its specific immunizing peptide should abolish specific staining. Sixth, validate staining patterns with multiple antibodies targeting different POLR3D epitopes to confirm consistent localization patterns. Finally, include functional controls in stimulated versus unstimulated cells, as POLR3D redistribution between compartments may occur during immune activation in response to viral or bacterial DNA.

How should researchers interpret unexpected molecular weight bands when using POLR3D antibodies in Western blotting?

When encountering unexpected molecular weight bands in Western blots using POLR3D antibodies, researchers should follow a systematic interpretation approach. The canonical molecular weight of POLR3D is approximately 44 kDa , and this should be the primary band observed. For lower molecular weight bands, consider potential proteolytic cleavage products – improve sample preparation by adding fresh protease inhibitors and reducing sample processing time/temperature. For higher molecular weight bands, evaluate possible post-translational modifications like ubiquitination, SUMOylation, or phosphorylation that could alter migration. To determine if bands represent specific POLR3D detection, conduct peptide competition assays, where pre-incubation of the antibody with its immunizing peptide should eliminate specific bands. Additionally, genetic validation through siRNA or CRISPR-based approaches should reduce or eliminate specific bands. To distinguish between isoforms and non-specific binding, compare patterns across multiple POLR3D antibodies targeting different epitopes. For complex-associated detection, consider whether crosslinking or incomplete denaturation might be occurring. Finally, validate findings through correlation with functional assays – does the abundance of particular bands correlate with POLR3D transcriptional activity or immune sensing function in your experimental system?

What is the comparative specificity and sensitivity data for different POLR3D antibodies in detecting endogenous protein?

Comparative analysis reveals that both antibodies demonstrate the ability to detect endogenous POLR3D protein in human cell lines, with the ab86786 antibody showing validation across a broader range of applications including immunoprecipitation and immunohistochemistry . The PACO22314 antibody offers additional ELISA applications with high dilution capabilities, suggesting potentially higher sensitivity in this format . Both antibodies target internal regions of the protein, which may confer stability in detection across different experimental conditions. When selecting between these antibodies, researchers should consider their specific application requirements, with ab86786 potentially offering greater versatility across techniques , while PACO22314 may provide advantages for quantitative ELISA-based approaches .

How do experimental conditions affect POLR3D antibody performance in studying viral immune responses?

Experimental conditions significantly impact POLR3D antibody performance when studying viral immune responses. Temperature and timing are critical variables – POLR3D's innate immune function is activated upon viral infection, causing dynamic redistribution between nuclear and cytosolic compartments that can affect epitope accessibility . Fixation methods dramatically influence results: for immunofluorescence studies, paraformaldehyde fixation (typically 4%) preserves protein localization while maintaining antigenicity, whereas methanol fixation may better expose certain epitopes but potentially disrupt protein complexes. Buffer composition requires optimization: for immunoprecipitation of immune complexes, lower stringency buffers (150mM NaCl, 0.5% NP-40) may preserve physiologically relevant interactions, while higher stringency conditions may be needed to reduce background . Experimental stimulation protocols affect results: researchers should standardize viral infection parameters (MOI, time post-infection) when comparing POLR3D responses across experiments. For studying the Epstein-Barr virus-specific response, timing is particularly important as POLR3D's interaction with EBERs and subsequent activation of the RIG-I pathway follows specific kinetics . Finally, cell type substantially impacts performance – immune cells may exhibit different POLR3D expression levels and subcellular distribution patterns compared to other cell types, necessitating antibody dilution optimization for each experimental system.

How can POLR3D antibodies be applied to study the role of RNA polymerase III in cancer biology?

POLR3D antibodies offer powerful tools for investigating RNA polymerase III's emerging roles in cancer biology through multiple experimental approaches. First, researchers can utilize immunohistochemistry with validated antibodies like ab86786 (1/1000 dilution) to assess POLR3D expression patterns across tumor types, grades, and stages, potentially identifying expression signatures associated with prognosis or treatment response. Second, chromatin immunoprecipitation (ChIP) using POLR3D antibodies can map genome-wide binding patterns in normal versus cancer cells, revealing cancer-specific transcriptional programs. Third, proximity ligation assays (PLA) with POLR3D antibodies can uncover novel protein-protein interactions specific to the cancer context. Fourth, immunoprecipitation followed by mass spectrometry can identify cancer-specific POLR3D interaction partners that might represent therapeutic targets. Fifth, researchers can examine the dual functionality of POLR3D in cancer contexts – is its role in transcribing tRNAs and other small RNAs supporting cancer cell proliferation, or is its innate immune sensing function dysregulated in cancer cells, potentially allowing immune evasion? Finally, POLR3D antibodies can be applied to patient-derived samples to correlate expression patterns with clinical outcomes, treatment responses, and genetic alterations, potentially leading to POLR3D as a diagnostic or prognostic biomarker.

What novel applications are emerging for POLR3D antibodies in studying autoimmune disorders?

Novel applications for POLR3D antibodies in autoimmune research are emerging as the link between nucleic acid sensing and autoimmunity becomes increasingly recognized. First, immunohistochemistry and immunofluorescence with POLR3D antibodies (such as ab86786 at 1/1000 dilution) can map expression and localization patterns in tissues from autoimmune disease models and patient samples, potentially identifying dysregulation of this nucleic acid sensor. Second, co-immunoprecipitation studies using POLR3D antibodies can identify aberrant protein-protein interactions in autoimmune contexts, particularly focusing on the RIG-I pathway components that interact with POLR3D during immune responses . Third, researchers can implement flow cytometry with POLR3D antibodies to quantify expression levels in specific immune cell subsets from autoimmune patients, correlating with disease activity. Fourth, cutting-edge approaches like spatial transcriptomics combined with POLR3D immunostaining can reveal tissue-specific dysregulation patterns. Fifth, chromatin immunoprecipitation sequencing (ChIP-seq) with POLR3D antibodies can identify altered genomic binding patterns in autoimmune conditions. Sixth, single-cell approaches coupling POLR3D detection with cytokine profiling can reveal how aberrant nucleic acid sensing might drive inflammatory programs. Finally, therapeutic targeting studies can utilize POLR3D antibodies to monitor target engagement and pathway modulation in preclinical models of autoimmunity where aberrant nucleic acid sensing contributes to pathology.